News about Global Pharma

IDEAYA Biosciences Enrols First Patient in Phase I Trial of IDE034 Bispecific TOP1 ADC

Precision oncology firm IDEAYA begins Phase I evaluation of IDE034, a PTK7/B7H3 bispecific TOP1 ADC, advancing its ADC and DNA damage response combination strategy in solid tumours.

Global Pharma | 02/03/2026 | By News Bureau |  155

China Approves Jaypirca for Relapsed CLL and SLL Patients

Jaypirca (pirtobrutinib) by Innovent Biologics has been approved in China for the treatment of adults with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The BTK inhibitor is designed to overcome resistance associated with prior covalent BTK therapies.

Global Pharma | 02/03/2026 | By News Bureau |  137

Japan's MHLW accepts GSK's Bepirovisen for Review to Treat Chronic Hepatitis B

Japan’s health ministry has accepted GSK’s new drug application for investigational antisense therapy bepirovirsen, after Phase III trials showed significantly higher functional cure rates in chronic hepatitis B patients.

Global Pharma | 27/02/2026 | By News Bureau |  592

India and Brazil Explore New Avenues to Strengthen Pharmaceutical Trade

India and Brazil are exploring new opportunities to expand bilateral pharmaceutical trade through enhanced regulatory cooperation and business engagement.

Global Pharma | 26/02/2026 | By Darshana |  174

Fortress Biotech Unit Cyprium to Sell Rare Pediatric PRV for USD 205 Million

Fortress Biotech Inc and its majority-owned subsidiary Cyprium Therapeutics Inc announced that Cyprium has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of USD 205 million, subject to closing.

Global Pharma | 25/02/2026 | By Darshana |  164

Worldwide Clinical Trials Completes Acquisition of Oncology-Focused CRO Catalyst Clinical Research

Worldwide Clinical Trials strengthens its oncology and early-phase research capabilities following the completion of its acquisition of Catalyst Clinical Research.

Global Pharma | 17/02/2026 | By News Bureau |  212

Sanofi Completes Acquisition of Dynavax, Expands Adult Vaccine Portfolio with HEPLISAV-B

Sanofi has finalised its acquisition of Dynavax, adding hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate to strengthen its global adult immunisation business.

Global Pharma | 12/02/2026 | By News Bureau |  232

Pfizer Joins BaseLaunch Biotech Incubator

Pfizer joins six leading pharma companies helping launch and grow exceptional biotech ventures.

Global Pharma | 12/02/2026 | By News Bureau |  289

FDA Accepts IND for Affinia's AFTX-201 Gene Therapy in BAG3 Dilated Cardiomyopathy

Affinia Therapeutics receives FDA clearance to begin clinical testing of AFTX-201, a next-generation AAV gene therapy for BAG3-associated dilated cardiomyopathy, with Phase 1/2 UPBEAT trial set to begin in 2026.

Global Pharma | 09/02/2026 | By News Bureau |  210

Health Canada Authorises Livmarli Tablet for Cholestatic Pruritus in Alagille Syndrome

Mirum Pharmaceuticals receives Health Canada approval for Livmarli tablet formulation, expanding dosing options for eligible Alagille syndrome patients with cholestatic pruritus.

Global Pharma | 07/02/2026 | By News Bureau |  161